NEW YORK — Australian genetic testing firm Incite Genomics said Tuesday that it has struck a deal with US-based Ethos Laboratories to commercialize its CNSDose pharmacogenomics test in North America.

纽约——澳大利亚基因检测公司Incite Genomics周二表示，已与美国Ethos Laboratories达成协议，将在北美市场推广其CNSDose药物基因组学测试。

Using a patient's cheek swab sample, CNSDose analyzes 19 genes related to liver drug metabolism and drug transport across the blood-brain barrier to help guide psychiatric medication decisions. The test's developer, also called CNSDose, was

使用患者的颊拭子样本，CNSDose分析与肝脏药物代谢和血脑屏障药物转运相关的19个基因，以帮助指导精神科药物决策。该测试的开发者也被称为CNSDose，

acquired

获得

by Incite Health, the parent firm of Incite Genomics,

由Incite Genomics的母公司Incite Health，

in early 2023

2023年初

.

。

Under the terms of the deal, Newport, Kentucky-based Ethos will exclusively commercialize and perform the test in North America. Financial and other terms were not disclosed.

根据协议条款，总部位于肯塔基州纽波特的 Ethos 将独家在北美商业化并进行该测试。财务条款及其他细节未披露。

A long-term randomized, controlled trial of CNSDose is on track for completion early in 2026, according to Incite Genomics.

根据Incite Genomics的消息，一项关于CNSDose的长期随机对照试验有望在2026年初完成。